Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients

BACKGROUND: The efficacy and safety of extended half-life, full-length, pegylated recombinant factor VIII rurioctocog alfa pegol [BAX 855, ADYNOVATE (USA)/ADYNOVI (Europe); Baxalta US Inc., a Takeda company, Lexington, MA, USA] was investigated in previously treated Korean patients with severe hemop...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Chur Woo, Baek, Hee Jo, Park, Sang Kyu, Park, Young Shil, Shin, Ho-Jin, Engl, Werner, Tangada, Srilatha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779944/
https://www.ncbi.nlm.nih.gov/pubmed/31730687
http://dx.doi.org/10.5045/br.2019.54.3.198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779944/
https://www.ncbi.nlm.nih.gov/pubmed/31730687
http://dx.doi.org/10.5045/br.2019.54.3.198

Ejemplares similares